CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1612422
This article is part of the Research TopicThe pathogenesis and novel treatment options in AIBDsView all 8 articles
Induced Pemphigus erythematosus after treatment for plaque psoriasis with secukinumab: a case report
Provisionally accepted
Fengming Hu1,2,3,4
Hong Peng2,3,4,5Jian Gong1,2,3,4
Xiaohua Tao1,2,3,4Xi Wang1,2,3,4Jianwei Bao1,2,3,4Pingxiu He1,2,3,4Lismin Dirwanto6
Liu Mingqiang1,2,3,4*
Hongbing Yang1,2,3,4*- 1Dermatology Hospital of Jiangxi Province, Jiangxi, China
- 2Jiangxi Provincial Clinical Research Center for Skin Diseases, JiangXI, China
- 3Candidate Branch of National Clinical Research Center for Skin Diseases, JiangXI, China
- 4The Affiliated Dermatology Hospital of Nanchang University, JiangXI, China
- 5School of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province, China
- 6International Education College, Jiangxi University of Chinese Medicine, JiangXI, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes interleukin (IL)-17A, a cytokine typically involved in the mucocutaneous defense against pathogens. Despite its favorable safety profile, serious adverse events such as inflammatory bowel disease, oral pemphigoid-like lesions, and lupus erythematosus have been reported. While widely used for psoriasis treatment, cytokine-based therapies carry a potential risk of triggering autoimmune responses. The precise mechanism by which secukinumab induces pemphigus erythematosus remains unclear but may involve immune dysregulation, autoantibody production, microbiota influences, and genetic susceptibility. We report a case of pemphigus erythematosus occurring in a psoriasis patient during secukinumab therapy, which improved after treatment with methylprednisolone sodium succinate injection, leading to clinical symptom resolution. Clinicians should remain vigilant for potential complications and develop individualized management strategies for patients receiving secukinumab.
Keywords: Pemphigus erythematosus, secukinumab, adverse drug event, Psoriasis, autoimmune disease
Received: 28 Apr 2025; Accepted: 27 Aug 2025.
Copyright: © 2025 Hu, Peng, Gong, Tao, Wang, Bao, He, Dirwanto, Mingqiang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liu Mingqiang, Dermatology Hospital of Jiangxi Province, Jiangxi, 330000, China
Hongbing Yang, Dermatology Hospital of Jiangxi Province, Jiangxi, 330000, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.